acute exacerbation of Chronic Obstructive Pulmonary Disease with Chronic Pulmonary Heart Disease
Conditions
Interventions
Routine therapy group:Routine therapy
Low molecular weight heparin group:Low molecular weight heparin
Sodium Tanshinone IIA Sulfonate group:Sodium Tanshinone IIA Sulfonate (STS)
Sponsors
First Affiliated Hospital of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with AECOPD with pulmonary heart disease; 2. Male or female between 40 to 80 years old; 3. Patients volunteered for this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with other pulmonary diseases except COPD, Such as pneumonia, pneumothorax, pleural effusion,pulmonary embolism; 2. Patients with advanced cancer or suspected lung cancer; 3. Patients with pulmonary lobectomy; 4. Patients with acute myocardial infarction, congestive heart-failure and other acute heart diseases; 5. Patients who have to take anticoagulant, antiplatelet and Pulmonary Hypertension drugs during the period of treatment; 6. Patients who have to take other drugs containing reduced pulmonary hypertension such as calcium channel blockers, angiotensin converting enzyme inhibitors; 7. Patients who had used anticoagulant, antiplatelet and/or reducing the pulmonary hypertension drugs within 2 weeks before admission; 8. Patients with severe hemorrhage, and hemorrhagic tendency; 9. Unavailable or limited legal capacity; 10. Pregnant or lactational women; 11. Important organs with severe diseases; 12. Mental or physical disability; 13. With suspected or indeed alcohol, drug abuse history; 14. With allergic constitution, with two or more drugs or foods allergy history or those who are allergic to any components of the experimental drugs; 15. With both aspartate aminotransferase (AST) and glutamic-pyruvic transaminase (ALT) more than three times of the upper limit of normal in liver function test and Ccr less than at least 50ml/min in kidney function test; 16. Those with systemic blood pressure lower than 90/50 mmHg, or those uncontrolled dangerous hypertension (BP higher than 170/110 mmHg); 17. Patients at active stages of infectious or other diseases such as hepatitis A, hepatitis B, AIDS, tuberculosis, and some connective tissue diseases; 18. Patients with severe infection, especially pulmonary infection; 19. Patients with shock or astable hemodynamics with other causes; 20. Patients with hepatic cirrhosis, and hepatic cirrhosis induced portal hypertension; 21. Patients cannot accomplish required items (especially 6MWD) because of acute/chronic organic disease (excluding dyspnea) or other illnesses such as lower extremity diseases; 22. Patients with any other conditions considered cannot be recruited.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PASP, RV at 0 and 11 days of trial by echocardiogra;coagulation function;mMRC;IRTI; | — |
Secondary
| Measure | Time frame |
|---|---|
| P-selectin and endothelin-1;arterial blood gases, blood routine, Nt-proBNP, CTnT;6-minute walk distance and BMI;Putum cytologic examination;Sputum cytologic examination; TNF-ahpha, IL-6 and IL-8; | — |
Countries
China
Contacts
Public ContactJian Wang
Outcome results
None listed